DEALS: Angiotech follows a combinational route

DEALS

WHO

WITH

WHAT

SCOOP

Angiotech Pharmaceuticals

American Medical Instruments

$785 million cash buyout

The deal expands Angiotech's drug development business with combinational devices and gives it a bigger sales force in the bargain.

SuperGen

Montigen

$18M buyout

Montigen's assets include its R&D team, a proprietary drug discovery technology platform and optimization process, and preclinical compounds targeting aurora-A kinase and members of the tyrosine kinase receptor family.

GeoVax

Dauphin Technology

Merger

Emory University emerges as the largest shareholder in venture aimed at developing an AIDS vaccine.

Par Pharmaceutical

FineTech Laboratories

Divestiture

FineTech has been transferred to Arie L. Gutman, Ph.D., president and CEO of FineTech.

Clearview

BioMachines

Acquisition of majority control

The deal is a vote of confidence in BioMachines' future in diagnostics.

AngioGenex

eClic

Reverse merger

The merger allows AngioGenex to go public.